Baricitinib, an oral dual JAK1/2 inhibitor, has proven effective in rheumatoid arthritis (RA) by blocking IL−6/JAK/STAT signaling and reducing structural joint damage. The gene discussed is JAK1; the disease is rheumatoid arthritis.